Eli Lilly and Company and Boehringer Ingelheim GmbH's diabetes treatment Jardiance (empagliflozin) may be poised for a broad heart failure indication after the drug showed a statistically significant benefit in a Phase III trial in a setting where Novartis AG's heart failure drug Entresto (sacubitril/valsartan) and other rivals have not.
The companies announced positive top-line data on 6 July from a Phase III trial, EMPEROR-Preserved. The data showed Jardiance reduced...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
